Clinical trial · Observational
Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
NCT04549584CI-TRIAL-00048900NEO-SMARTterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): due to poor enrolled patients
Summary
Brief summary (as posted)
prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metaplastic Breast Carcinoma | Breast Metaplastic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vimentin/pan CK stain | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- metaplastic breast cancer
- description
- Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
- interventionNames
- Diagnostic Test: Vimentin/pan CK stain
- label
- non-metaplastic breast cancer
- description
- Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer
Primary outcomes (1)
- measure
- response rate of neoadjuvant chemotherapy
- timeFrame
- After neoadjuvant chemotherapy was finished. Average 6 month later.
- description
- response criteria for neoadjuvant chemotherapy-complete response (CR), partial response (PR), and no response (NR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * over 20 years old * patients with triple negative breast cancer diagnosed Seoul National University Hospital * patients who decided to perform neoadjuvant chemotherapy under clinical judgement Exclusion Criteria: * not applicable
References
Publications (3)
- BACKGROUNDSatelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011 Sep;68(18):3033-46. doi: 10.1007/s00018-011-0735-1. Epub 2011 Jun 3. PMID 21637948
- BACKGROUNDSchwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol. 2013 Nov 14;2(1):31. doi: 10.1186/2162-3619-2-31. PMID 24499560
- BACKGROUNDAdams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer. 2017 Mar 29;3:8. doi: 10.1038/s41523-017-0011-0. eCollection 2017. PMID 28649648